Geographic Atrophy

A checklist could help keep patients with geographic atrophy on track.

Sessions at the 1-4 October Vienna congress address GA patient selection, AI-based functional prediction, imaging biomarkers, and surgical intervention.

Q3 2026 delivered advances in some closely watched pipeline products.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.

For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the clinic with a broader view of the field.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal lesions, with no drug-related serious adverse events.

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.

Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

ARCHER data reveal which GA eyes risk major vision loss: midrange baseline acuity and subfoveal lesions, shaping counseling and future AMD trials.

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.

The randomized, double-masked, 3-arm trial did not achieve its primary endpoint of replicating the visual function improvements observed in a smaller phase 1/2a study.

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about a photovoltaic subretinal implant showing meaningful visual gains in patients with geographic atrophy due to AMD.

From a phase 3 durability readout for a first-in-class TKI to a new interchangeable ranibizumab biosimilar and a deep dive into geographic atrophy management, June brought a wide-ranging mix of regulatory, clinical, and practice-pattern news for retina specialists

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Border zone lifetime gradient correlated with growth rate over 5 years

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.

In a preference study, Csaky and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

Not every question in the management of patients with GA has a clear answer—the two retina specialists work through the ones clinicians face most often in practice.

A prospective pilot study finds focal photopic microperimetry may detect cone-mediated losses that lesion size and visual acuity do not reflect.

A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy.